(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 7.15% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.67%.
Abbvie's revenue in 2025 is $58,328,000,000.On average, 10 Wall Street analysts forecast ABBV's revenue for 2025 to be $107,127,524,884,606, with the lowest ABBV revenue forecast at $106,828,971,240,174, and the highest ABBV revenue forecast at $107,971,566,985,748. On average, 10 Wall Street analysts forecast ABBV's revenue for 2026 to be $117,374,129,817,205, with the lowest ABBV revenue forecast at $114,679,662,110,001, and the highest ABBV revenue forecast at $120,331,556,786,601.
In 2027, ABBV is forecast to generate $126,554,184,037,347 in revenue, with the lowest revenue forecast at $121,751,194,796,760 and the highest revenue forecast at $132,106,096,816,501.